Advertisement

Picture [iito] Back into Ad 650x80px
Organisation › Details

Argenx SE (Euronext + Nasdaq: ARGX)

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates. *

 

Period Start 2019-03-28 renamed before
  Group Argenx (Argen-X) (Group)
  Predecessor Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
Products Industry therapeutic antibody
  Industry 2 SIMPLE Antibody™ discovery platform
Persons Person Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)
  Person 2 Gubitz, Karl (Argenx 202106– CFO before at Pfizer since 2003 before PircewaterhouseCoopers)
     
Region Region Breda
  Country Netherlands
  Street 5 Willemstraat
  City 4811 AH Breda
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2022-03-01)
  Currency USD
  Annual sales 539,418,000 (income, operating, consolidated (2021) 2021-12-31)
  Profit -408,265,000 (2021-12-31)
  Cash 2,336,728,000 (2021-12-31)
     
    * Document for �About Section�: Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent.
     
   
Record changed: 2022-04-01

Advertisement

Picture [iito] Fighting Customers 650x100px

More documents for Argenx (Argen-X) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 650x80px




» top